Alzheimers Disease Ad Pipeline Insight
DelveInsight’s, “Alzheimer’s Disease (AD) – Pipeline Insights, 2021,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Alzheimer’s Disease (AD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Alzheimer’s Disease (AD) Understanding
Alzheimer’s Disease (AD): Overview
Alzheimer’s Disease (AD) is a slowly progressive brain disease that begins many years before symptoms emerge. It is the most common cause of dementia, accounting for an estimated 60% to 80% of cases. The hallmark pathologies of Alzheimer's disease are the accumulation of the protein fragment beta‐amyloid (plaques) outside neurons in the brain and twisted strands of the protein tau (tangles) inside neurons. These changes are accompanied by the death of neurons and damage to brain tissue. On the basis of severity, this degenerative disease can be classified as mild, moderate, and severe.
Alzheimer’s disease is a progressive condition therefore the symptoms get worse over time. Memory loss is a key feature, and this tends to be one of the first symptoms to develop. Other symptoms are:
- Cognitive deficits.
- Problems with recognition
- Problems with spatial awareness
- Problems with speaking, reading, or writing
- Later symptoms include impaired communication, disorientation, confusion, poor judgment, behavioral changes and, ultimately, difficulty speaking, swallowing and walking.
- As the disease progresses, neurons in other parts of the brain are damaged or destroyed.
A diagnosis of Alzheimer’s Disease (AD) is made based upon a thorough clinical evaluation, a detailed patient history, and a variety of specialized tests. Means of diagnosing AD include clinical diagnosis which is usually made during the mild stage of the disease, Lumbar puncture, and Imaging studies.
Treatment for Alzheimer’s Disease (AD) includes options that may reduce the symptoms and help improve the quality of life. The U.S. Food and Drug Administration (FDA) has approved two types of medications — cholinesterase inhibitors (Aricept, Exelon, Razadyne) and memantine (Namenda) to treat the cognitive symptoms. Other non-pharmacological therapies are also used with the goal of maintaining or improving cognitive function, the ability to perform activities of daily living or overall quality of life.
Alzheimer’s Disease (AD) Emerging Drugs Chapters
This segment of the Alzheimer’s Disease (AD) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Alzheimer’s Disease (AD) Emerging Drugs
BAN2401 is the humanized IgG1 version of the mouse monoclonal antibody mAb158, which selectively binds to large, soluble Aβ protofibrils. BAN2401 selectively binds to neutralize and eliminate toxic Aβ protofibrils that are thought to be a causative factor for Alzheimer’s Disease. Eisai obtained the global rights to study, develop, manufacture and market BAN2401 for the treatment of Alzheimer's disease pursuant to an agreement concluded with BioArctic in December 2007.
- Gantenerumab: Hoffmann-La Roche
Gantenerumab is an investigational therapy designed to bind more specifically to aggregated forms of beta-amyloid and remove beta-amyloid plaques. Gantenerumab was originally developed by Chugai Pharmaceuticals, which is now part of Hoffmann-La Roche. This treatment is administered as an injection under the skin, is now being developed by Hoffmann-La Roche in collaboration with MorphoSys.
Further product details are provided in the report……..
Alzheimer’s Disease (AD): Therapeutic Assessment
This segment of the report provides insights about the different Alzheimer’s Disease (AD) drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Alzheimer’s Disease (AD)
There are approx. 100+ key companies which are developing the therapies for Alzheimer’s Disease (AD). The companies which have their Alzheimer’s Disease (AD) drug candidates in the most advanced stage, i.e. phase III include, Eisai.
DelveInsight’s report covers around 100+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Alzheimer’s Disease (AD) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Alzheimer’s Disease (AD): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Alzheimer’s Disease (AD) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Alzheimer’s Disease (AD) drugs.
- The companies and academics are working to assess challenges and seek opportunities that could influence Alzheimer’s Disease (AD) R&D. The therapies under development are focused on novel approaches to treat/improve Alzheimer’s Disease (AD).
- In December 2019, BioArctic announced the initiation of a research collaboration with Eisai aimed at further studying the unique profile of the investigational drug candidate BAN2401. The research collaboration with Eisai is in addition to the existing development and commercialization agreement for BAN2401. This new collaboration is intended to further characterize the unique binding profile of BAN2401.
Alzheimer’s Disease (AD) Report Insights
- Alzheimer’s Disease (AD) Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Alzheimer’s Disease (AD) Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Alzheimer’s Disease (AD) drugs?
- How many Alzheimer’s Disease (AD) drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Alzheimer’s Disease (AD)?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Alzheimer’s Disease (AD) therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Alzheimer’s Disease (AD) and their status?
- What are the key designations that have been granted to the emerging drugs?
- Changchun Huayang High-tech Co. Ltd.
- Hoffmann-La Roche
- vTv Therapeutics
- AC Immune
- INmune Bio
- Cassava Sciences
- EIP Pharma
- AB Science
- Anavex Life Sciences
- Athira Pharma
- Time Therapeutics
- Prilenia Therapeutics
- Denali Therapeutics Inc.
- Elenbecestat (E2609)
- Octohydroaminoacridine Succinate
- Azeliragon (TTP488)
- Donepezil/memantine extended release
- Pegylated exenatide